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Abstract: Arginine is a constituent of proteins and a precursor for polyamines and nitric oxide, and is
essential for placentation, angiogenesis, and growth. Maternal plasma arginine concentrations
are found to be lower in pregnancies complicated by fetal growth restriction, and arginine
supplementation in later pregnancy is reported to increase birth weight. We measured arginine
and the metabolites asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA)
in the amniotic fluid obtained in pregnancy weeks 13 to 15 from 363 pregnancies with a documented
normal outcome and related the concentrations to birth weight, length, and head circumference.
Arginine was higher in the amniotic fluid from female (mean 40.8 (SD 10.6) µmol/L) compared to
male fetuses (37.4 (SD 11.2) µmol/L, p = 0.003). Despite the gender difference, arginine in the amniotic
fluid from gestational weeks 13–15 was the strongest predictor for birth weight, length, and head
circumference. ADMA was a strong predictor for birth weight and length, SDMA for birth weight,
while Arg/ADMA and Arg/SDMA only predicted head circumference in multiple linear regression
models. Due to increased arginine demands, pregnancy is considered a state of relative arginine
deficiency. Our findings reflect the importance of a good maternal arginine status in early pregnancy,
an observation that should be evaluated in an intervention study.
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1. Introduction
Arginine plays an essential role in fetal and placental development and is reported to be abundant
in the amniotic fluid in early pregnancy [1–3] Arginine serves as a building block of proteins and a key
regulator of several metabolic pathways [4]. Arginine is hydrolyzed to ornithine and converted into
the polyamines putrescine, spermine, and spermidine [5], key regulators of placental angiogenesis,
trophoblast growth, and embryogenesis [6].
Arginine is additionally the substrate for the production of nitrix oxide (NO), and asymmetric
dimethylarginine (ADMA), a guanindine (NG)-dimethylated derivate of arginine, is a strong direct
inhibitor of nitric oxide synthase (NOS). Symmetric dimethylarginine (SDMA) is an indirect and
weaker inhibitor of NOS and a marker of renal function. The ratio Arg/ADMA is considered to be
a marker of NOS activity [7], and a low ratio is regarded as a marker of endothelial dysfunction [8].
Pregnancy is associated with enhanced vasodilatation, and NO has been assigned a particular role
in the physiological vascular adaptation [9] that is considered to be essential for the formation of a
healthy endothelium and for promoting the endovascular invasion by the cytotrophoblast [10].
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Due to the increased needs for arginine for placental and fetal growth [11], pregnancy is considered
to be a state of relative arginine deficiency [12]. Maternal plasma arginine concentrations were found
to be lower in pregnancies complicated by fetal growth restriction [13,14].
Before keratinization of the fetal skin occurs around gestational week 20, the composition of the
amniotic fluid is considered to reflect the metabolite profile of fetal plasma and provides a rational
compartment for studies of fetal nutrition and metabolism [1].
We have measured arginine and the metabolites ADMA and SDMA in amniotic fluid obtained
in pregnancy weeks 13 to 15 from pregnancies with a documented normal outcome. The aim of the
study was to evaluate the relation between these amino acids and the final birth weight, length, and
head circumference.
2. Materials and Methods
Samples of amniotic fluid taken by transabdominal amniocentesis for genetic prenatal diagnosis
at Haukeland University Hospital, Bergen, Norway, during 1995 through 1998 were eligible for
this observational study. The gestational age was determined by menstrual dates and checked
by ultrasound examination. The information about pregnancy outcomes was collected from
questionnaires routinely returned after delivery. Samples from singleton pregnancies with a
documented normal outcome, obtained at gestational weeks 13, 14, and 15 were included in the
study (n = 371). Birth before gestational week 37 was defined as premature birth, and a birth weight
below 2500 grams at term was defined as small for gestational age (SGA).
The samples were stripped for identifiers, the procedures for information collection were in
accordance with the revised Helsinki declaration of 1983, and the study was granted approval by the
Regional Committee on Medical Research Ethics West (365/02).
2.1. Sampling and Biochemical Analysis
The samples were centrifuged after amniocentesis and stored at −20 ◦C until analyses were
done in 1999. Amniotic fluid concentrations of arginine, ADMA, and SDMA were measured using a
LC-MS/MS method [15] by the laboratory Bevital AS, Bergen Norway (www.bevital.no).
2.2. Statistical Analysis
Data are presented as mean and SD and compared by ANOVA test, or as median and interquartile
range (IQR) and compared by Kruskal–Wallis test. Multiple linear regression models, corrected for
gender, gestational age at sampling, and storage period were used to explore the relationships between
amniotic fluid arginine, ADMA, or SDMA concentrations and growth parameters at birth (weight,
length, and head circumference). Graphical illustrations of the relationships between arginine or the
methylarginines and birth weight were obtained by generalized additive models (GAM), corrected for
gender, gestational age at sampling, and storage period.
The SPSS statistical program (version 23) and the package “mgcv” in R, version 3.3 (The R
Foundation for Statistical Computing, Vienna, Austria) were used for the statistical analyses. Two-sided
p-Values < 0.05 were considered statistically significant.
3. Results
3.1. Characteristics of the Study Population
The main indication for amniocentesis was maternal age (Table 1). The infants were healthy and
born at term with an appropriate weight for gestational age, apart from three infants (0.8%) who were
born premature and six term-born infants (1.6%) who were defined SGA. These nine infants were
excluded, thereby leaving amniotic fluid from 363 pregnancies with a documented normal outcome
eligible for the study.
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The mean birth weight was higher in boys compared to girls (3713 (SD 562) versus 3592 (SD 468)
g, p = 0.03), and the same pattern was seen for birth length (50.8 (SD 2.8) versus 49.9 (SD 2.4) cm,
p = 0.005) and head circumference (35.7 (SD 1.4) versus 35.2 (SD 1.5), cm, p = 0.008).
Table 1. Characteristics of the population (n = 363).
Indications for Amniocentesis
Maternal age > 38 years, n (%) 315 (87)
Previous child with chromosomal aberration or malformation, n (%) 31 (8)
Maternal epilepsy, n (%) 6 (2)
Other, n (%) 11 (3)
Maternal age, years, median (total range) 39.0 (24.0–45.0)
Gestational age, week, median (total range) 14.0 (13.0–15.0)
Male sex, n (%) 180 (50)
Birth weight, g, mean (SD) 3650 (520)
Birth length, cm, mean (SD) 50.3 (2.6)
Head circumference, cm, mean (SD) 35.5 (1.4)
Apgar score 1, mean (SD) 9 (1)
Apgar score 2, mean (SD) 9 (1)
3.2. Arginine and Metabolite Concentrations According to Gestational Age
The mean arginine (−13%), ADMA (−15%), and SDMA (−10%) concentrations decreased
significantly from gestational week 13 to 15, while no such trend was seen for the ratios Arg/ADMA
and Arg/SDMA (Table 2). The storage time varied from 1 to 4 years, with no difference according to
the gestational week at sampling (p = 0.41).
Table 2. Concentrations of arginine, asymmetric dimethylarginine (ADMA), and symmetric
dimethylarginine (SDMA) in amniotic fluid (n = 363) according to the pregnancy week.
Parameters
Pregnancy Week p-Value
13 (n = 110) 14 (n = 217) 15 (n = 36)
Sampling year 1996 (1995–1997) 1996 (1995–1997) 1996 (1995–1996) 0.26 *
Arginine, µmol/L 41.3 (11.4) 38.4 (11.1) 36.0 (8.3) 0.019 **
Asymmetric dimethylarginine, µmol/L 2.71 (0.52) 2.66 (0.49) 2.28 (0.38) <0.001 **
Symmetric dimethylarginine, µmol/L 1.59 (0.34) 1.59 (0.33) 1.41 (0.31) 0.008 **
Arg/ADMA 15.2 (3.3) 14.5 (3.4) 16.1 (4.0) 0.015 **
Arg/SDMA 26.6 (7.7) 24.7 (7.0) 26.6 (7.8) 0.041 **
* The values are given as median (IQR) and compared by the Kruskal–Wallis test. ** The values are given as mean
(SD) and compared by ANOVA.
3.3. Arginine and Metabolite Concentrations According to Gender
The mean arginine concentrations were higher in the amniotic fluid from female (40.8 (SD 10.6)
µmol/L) compared to male fetuses (37.4 (SD 11.2) µmol/L, p = 0.003), whereas no differences were
seen for ADMA (p = 0.16) and SDMA (p = 0.30) according to gender.
The mean Arg/ADMA ratio was higher in the amniotic fluid from female (15.3 (SD 3.3)) compared
to male fetuses (14.4 (SD 3.5), p = 0.007), whereas no significant difference according to gender was
seen in the Arg/SDMA ratio (p = 0.07).
3.4. Arginine and Metabolite Concentrations as Determinants for Birth Weight, Length, and
Head Circumference
Birth weight was positively correlated to arginine (r = 0.23, p < 0.001) and ADMA (r = 0.25,
p < 0.001), weakly correlated to SDMA (r = 0.17, p = 0.001), and not correlated to Arg/ADMA (p =
0.26) and Arg/SDMA ratios (p = 0.21) by Spearman correlation. Positive correlations were also seen
for birth length versus arginine (r = 0.14, p = 0.02), ADMA (r = 0.18, p = 0.002), and SDMA (r = 0.12,
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p = 0.04), but not versus Arg/ADMA (p = 0.97) or Arg/SDMA (p = 0.66) ratios. Head circumference
was positively correlated only to arginine (r = 0.17, p = 0.01).
Amniotic fluid arginine was the strongest predictor for birth weight, length, and head
circumference in multiple linear regression models which additionally included gender, gestational
week, and storage period (Table 3). ADMA was a strong predictor for birth weight and length, SDMA
for birth weight, while the ratios Arg/ADMA and Arg/SDMA were significant predictors only for
head circumference (Table 3).
Table 3. Arginine and metabolites in the amniotic fluid as determinants of birth weight, length, and










B 95% CI p-Value B 95% CI p-Value B 95% CI p-Value
Arginine 116 (69, 174) <0.001 0.4 (0.1, 0.7) 0.01 0.3 (0.1, 0.4) 0.003
ADMA 99 (50, 147) <0.001 0.3 (0.1, 0.6) 0.02 0.2 (−0.03, 0.3) 0.094
SDMA 68 (19, 116) 0.006 0.3 (0.0, 0.6) 0.06 0.1 (−0.1, 0.3) 0.24
Arg/ADMA 30 (−18, 79) 0.22 0.04 (−0.2, 0.3) 0.79 0.2 (0.0, 0.3) 0.05
Arg/SDMA 57 (9, 105) 0.02 0.07 (−0.2, 0.4) 0.64 0.2 (0.01, 0.3) 0.03
* Separate models were used for each amino acid and for the ratios. Each model additionally contained gender,
gestational age, and storage period. Amino acids and ratios were categorized as quartiles.
Birth weight (p < 0.001), length (p = 0.19), and head circumference (p = 0.05) increased with
increasing arginine concentrations in the amniotic fluid (Figure 1).
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A dose–response relationship between birth weight and arginine, ADMA, and SDMA was
visualized by GAM curves corrected for gender, gestational week, and storage time (Figure 2).
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from one study on amniotic fluid from pregnancy week 15, mean 34.8 (SD 12) µmol/L [21].
Nutrients 2017, 9, 1357 6 of 8
4.4. Arginine, ADMA, and SDMA in the Amniotic Fluid Compared to Maternal Plasma and Cord Blood
Amniotic fluid volume increases from about 25 mL at 10 weeks to about 400 mL at 20 weeks.
Before keratinization of the fetal skin, amino acids and other nutrients diffuse into the amniotic fluid
from the placenta through the placental membranes, and from the fetal circulation through the fetal
skin, and the composition of the amniotic fluid is considered to reflect that of fetal plasma [1].
However, the concentrations of arginine, ADMA, and SDMA that we observed in the amniotic
fluid differed substantially from the published concentrations in maternal plasma in early pregnancy
and in cord blood at term. The mean amniotic fluid arginine concentration at week 15 (36.0 (SD
8.3) µmol/L) was less than half (42%) of the one that was reported in maternal plasma at pregnancy
week 16 (estimated mean 85.5 (SE 4.6) µmol/L) [22], and in the umbilical cord vein at term (median 85.3
(IQR 69.7–95.0) µmol/L [22,23]. In pregnancy, there is a high demand for arginine for the production
of polyamines and NO [4], so the lower arginine levels in the amniotic fluid may reflect arginine
consumption by the placenta and the fetus. The placenta lacks arginase, a strategy which is suggested
to maximize the availability of arginine in the systemic circulation from mother to fetus [4].
The mean ADMA concentration in the amniotic fluid at week 15 (2.28 (SD 0.38) µmol/L) was
substantially higher (585%) compared to maternal plasma ADMA concentrations at pregnancy week
16 (estimated mean 0.39 (SE 0.02) µmol/L) [22], and substantially higher (178%) compared to the
umbilical cord vein at term (median 1.28 (IQR 1.18–1.38) µmol/L) [23]. Our mean SDMA in the
amniotic fluid at week 15 (1.41 (SD 0.31) µmol/L) was also higher (353%) than in maternal plasma
(estimated mean 0.40 (SE 0.02) µmol/L) [22], but slightly lower (83%) than in the umbilical cord vein
at term (median 1.69 (IQR 1.48–2.01) µmol/L) [23].
It has been suggested that the placenta is the primary source of ADMA present in fetal circulation
and that the observed high ADMA concentration may be a compensatory mechanism to stabilize the
high NO concentrations in the fetoplacental unit [23].
The amniotic fluid Arg/ADMA ratio at week 15 (16.1 (SD 4.0) was only 7% of reported maternal
plasma ratio in pregnancy week 16 (estimated mean 226.8, (SE 12.4)) [22], and 24% of reported median
umbilical cord vein ratio at term (66.0 (IQR 56.3–72.9) [23].
4.5. Arginine, ADMA, and SDMA as Determinants for Fetal Growth
Arginine was the strongest predictor for birth weight, length, and head circumference, followed
by gender. The metabolites ADMA and SDMA were weakly related to birth weight and length, while
the ratios Arg/ADMA and Arg/SDMA were weakly related to head circumference.
Published data on the relation between birth weight and amniotic fluid concentrations of arginine,
ADMA, and SDMA are missing. No significant correlations between circulating arginine, ADMA,
SDMA levels, and birth weight were seen in 130 neonates born premature (<30 gestational week) with
a very low birth weight (<1500 grams) [24]. However, maternal plasma arginine concentrations were
found to be lower in pregnancies complicated by fetal growth restriction [13,14].
Our findings reflect the importance of arginine in pregnancy, derived from its diverse functions,
both as a constituent of proteins and as a precursor for polyamines and NO, which make it essential for
growth and angiogenesis. An adequate concentration of arginine was shown to be crucial for placentation,
utero–placental blood flow and transfer of nutrients to the fetus, embryogenesis, and fetal growth
and development [25]. Arginine concentrations markedly increase in the uterine lumen during the
peri-implantation period of pregnancy [26,27], and arginine is also abundant in the conceptus [28]. The
placental synthesis of both NO and polyamines in animal studies was found to be highest during early
gestation when placental growth is most rapid [5,29,30]. Whether this is the case for humans is unknown.
Both animal and human studies have shown enhanced placental–fetal development and
growth after arginine supplementation in pregnancy [31–33]. The human studies were done in
pregnancies with a diagnosis of gestational hypertension [31] or intrauterine growth retardation [32,33].
The supplementation was initiated in middle or late pregnancy and was associated with increased
birth weight [32,33], reductions in diastolic blood pressure, and prolonged pregnancy [31].
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5. Conclusions
Arginine in the amniotic fluid from gestational weeks 13 to 15 was found to be a strong predictor
of birth weight, length, and head circumference, while ADMA was a predictor for birth weight and
length and SDMA only for birth weight.
Our findings reflect the importance of arginine metabolism in pregnancy, because of its diverse
functions, both as a constituent of proteins and as a precursor for polyamines and NO, which make it
essential for placentation, angiogenesis, and growth. Whether an improved maternal arginine status in
early pregnancy may enhance fetal growth, should be evaluated in an intervention study.
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